Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Thomas Emm"'
Autor:
Maria Danielsen, Thomas Emmanuel, Morten Muhlig Nielsen, Lise Maria Lindahl, Maria Gluud, Niels Ødum, Line Raaby, Torben Steiniche, Lars Iversen, Rikke Bech, Terkild Brink Buus, Claus Johansen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe majority of patients with mycosis fungoides (MF) have an indolent disease course, but a substantial fraction (20-30%) of patients progress to advanced stages – usually with a grave prognosis. Early differentiation between indolent a
Externí odkaz:
https://doaj.org/article/032ca7a08f2441cebfb7829eb806389e
Autor:
Zhenzhen Zhang, Liang Gao, Alexander Boes, Barbara Bajer, Johanna Stotz, Lina Apitius, Felix Jakob, Erik S. Schneider, Evgeni Sperling, Martin Held, Thomas Emmler, Ulrich Schwaneberg, Volker Abetz
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Continuous-flow biocatalysis utilizing immobilized enzymes emerged as a sustainable route for chemical synthesis. However, inadequate biocatalytic efficiency from current flow reactors, caused by non-productive enzyme immobilization or enzym
Externí odkaz:
https://doaj.org/article/d99ffd88bb234f94a89aa0bf68178d4d
Autor:
Elvin Aliyev, Thomas Emmler, Jelena Lillepaerg, Sergey Shishatskiy, Nadir Dizge, Volkan Filiz
Publikováno v:
ACS Omega, Vol 9, Iss 13, Pp 15282-15293 (2024)
Externí odkaz:
https://doaj.org/article/b78c45656c2d4d158cf2f5ff7b6bc4a3
Autor:
Fiona Lee, Xuejun Chen, Thomas Emm, Naresh Punwani, Swamy Yeleswaram, Yvonne Lo, William V. Williams, Peggy Scherle, Jack G. Shi
Publikováno v:
The Journal of Clinical Pharmacology. 54:1354-1361
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is currently in clinical development for the treatment of rheumatoid arthrit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bef9ff126e4803451215ce09d17f5539
https://doi.org/10.1002/jcph.354
https://doi.org/10.1002/jcph.354
Publikováno v:
JEADV Clinical Practice, Vol 1, Iss 4, Pp 307-316 (2022)
Abstract Psoriasis is a chronic inflammatory skin disease, in which molecular and cellular changes retain following clinical resolution of psoriatic lesions, a form of disease memory (‘molecular scar’) that may reestablish the psoriatic inflammat
Externí odkaz:
https://doaj.org/article/5ec9ce105bc042ff8bd8c393c8f67df1
Autor:
Yvonne Lo, William V. Williams, Peggy Scherle, Xuejun Chen, Swamy Yeleswaram, Thomas Emm, Naresh Punwani, Robert R. Landman, Jack G. Shi, Ryan F. McGee
Publikováno v:
Clinical Pharmacology in Drug Development. 3:34-42
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK1&2 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0520bbc05e88d9e2ff0114023a123cc
https://doi.org/10.1002/cpdd.77
https://doi.org/10.1002/cpdd.77
Autor:
Swamy Yeleswaram, Naresh Punwani, Ryan F. McGee, Edward G. McKeever, Robert R. Landman, Thomas Emm, Xuejun Chen, Yvonne Lo, William V. Williams, Peggy Scherle, Jack G. Shi
Publikováno v:
The Journal of Clinical Pharmacology. 52:809-818
Ruxolitinib, a selective Janus kinase (JAK) 1&2 inhibitor in development for the treatment of myeloproliferative neoplasms, is primarily metabolized by CYP3A4. The effects of inhibition or induction of CYP3A4 on single oral dose ruxolitinib pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f22d1f4f44b4fa761054fa9b882c5533
https://doi.org/10.1177/0091270011405663
https://doi.org/10.1177/0091270011405663
Publikováno v:
Biomedical Chromatography. 25:1245-1251
A rapid, sensitive and selective bioanalytical method was developed for the simultaneous determination of fluoxetine and its primary metabolite norfluoxetine in human plasma. Sample preparation was based on supported liquid extraction (SLE) using met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9aff911b3cf03bdc68a5a6fdaab8bf7
https://doi.org/10.1002/bmc.1597
https://doi.org/10.1002/bmc.1597
Publikováno v:
Dermatopathology, Vol 9, Iss 2, Pp 82-93 (2022)
Immunohistochemical quantification of inflammatory cells in skin biopsies is a valuable tool for diagnosing skin diseases and assessing treatment response. The quantification of individual cells in biopsies is time-consuming, tedious, and difficult.
Externí odkaz:
https://doaj.org/article/6b6de25e761743c1b62677f006f34238
Autor:
Xuejun, Chen, Jack G, Shi, Thomas, Emm, Peggy A, Scherle, Ryan F, McGee, Yvonne, Lo, Robert R, Landman, Naresh G, Punwani, William V, Williams, Swamy, Yeleswaram
Publikováno v:
Clinical pharmacology in drug development. 3(1)
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK12 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f05fbccf01a1a3a08361431d95c4801
https://pubmed.ncbi.nlm.nih.gov/27128228
https://pubmed.ncbi.nlm.nih.gov/27128228